Stock NRSN NEUROSENSE THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News NeuroSense Therapeutics Ltd.

Equities

NRSN

IL0011809592

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
1.52 USD -5.00% Intraday chart for NeuroSense Therapeutics Ltd. -9.52% +93.63%
Apr. 18 NeuroSense Therapeutics Ltd. Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting CI
Apr. 11 NeuroSense Therapeutics Prices $4.5 Million Offering of Ordinary Shares, Warrants MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NeuroSense Therapeutics Ltd. Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
CI
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
AQ
NeuroSense Therapeutics Prices $4.5 Million Offering of Ordinary Shares, Warrants
MT
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
PR
NeuroSense Therapeutics Ltd. announced that it expects to receive $4.47 million in funding
CI
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
PR
NeuroSense Therapeutics Ltd. Collaborates with Lonza to Identify Exosome-Based Biomarkers, in Order to Advance Neurodegenerative Disease Treatments and Diagnostics
CI
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
AQ
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
PR
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
PR
Neurosense Therapeutics Ltd. Reports Additional Positive Results from Its ALS Phase 2B Paradigm Trial
CI
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
PR
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
PR
NeuroSense Gets Non-Compliance Notice From Nasdaq
MT
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
PR
NeuroSense Reports New Data, Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
AQ
Neurosense Therapeutics Ltd. Reports Additional Positive Efficacy Data from Further Evaluation of Its Phase 2B Als Trial
CI
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
PR
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability and Secondary Clinical Efficacy Endpoints
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NRSN Stock
  4. News NeuroSense Therapeutics Ltd.